Acumen initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Acumen (ABOS) with a Buy rating and $6 price target The firm says Acumen is developing sabirnetug, an anti-amyloid beta oligomer monoclonal antibody that targets the most neurotoxic species in Alzheimer’s disease. The compound has demonstrated “compelling” Phase 1 proof-of-mechanism data, the analyst tells investors in a research note. Lucid sees a “meaningful near-term value inflection” with the Phase 2 ALTITUDE-AD results expected in late 2026.